PGPengfei Gao

Pengfei Gao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pengfei Gao has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Local and systemic SP-D in IPF and SARD-ILD

    by Hengyun Li, Wei Wang, Fuyun Zhang, Jingqi Cao, Yi Gao, Chaofei Guo, Hongxia Hu, Nan Peng, Yingwei Zhu, Yimin Mao, et al.

  • Open Access

    Matrix metalloproteinases levels in induced sputum in IPF and CTD-ILD

    by Fuyun Zhang, Wei Wang, Hengyun Li, Jingqi Cao, Yi Gao, Chaofei Guo, Hongxia Hu, Yingwei Zhu, Yimin Mao, Tongsheng Wang, et al.

    The involvement of matrix metalloproteinases (MMPs) in the pathogenesis of interstitial lung disease (ILD) is well-supported, and circulating MMP-7 has bee

  • Open Access

    The prognostic nutritional index improves risk stratification for acute pulmonary embolism

    by Shuangping Li, Shenshen Huang, Wei Wang, Jing Zhang, Bo Chen, Kelei Guo, Chenglong Ma, Shuaihui Hou, Pengfei Gao, Yimin Mao


  • Open Access

    Induced sputum: current progress and prospect

    by Fuyun Zhang, Huanhuan Wang, Wei Wang, Yingwei Zhu, Yimin Mao, Tongsheng Wang, Pengfei Gao

    Induced sputum is a noninvasive, safe, cost-effective, and reproducible method that is particularly advantageous for individuals who do not naturally produce sputum or provide inadequate samples. Its higher quality than spontaneously produced sputum makes it valuable in various respiratory conditions such as chronic obstructive pulmonary disease, asthma, lung cancer, and infectious respiratory diseases. Despite its potential, the clinical use of induced sputum is limited. In conditions like interstitial lung disease, where patients often have a dry cough, induced sputum shows promise, albeit with limited research. This review emphasizes the usefulness of induced sputum in such conditions, aiming for induced sputum to be established as a routine supplementary examination in clinical settings.


  • Analysis of clinical characteristics in 1940 patients with acute pulmonary embolism

    by Bo Chen, Wei Wang, Wenqian Zang, Jinjin Hu, Hengyun Li, Cong Wang, Yingwei Zhu, Yimin Mao, Pengfei Gao


  • Open Access

    Ficolin-1 ameliorates pulmonary fibrosis via directly binding to TGF-β1

    by Pengfei Gao, Yanjiao Lu, Kun Tang, Wei Wang, Tongsheng Wang, Yingwei Zhu, Jianping Zhao, Yimin Mao

    Ficolins were originally identified as proteins that bind to transforming growth factor-β1 (TGF-β1). They are capable of activating the complement system through lectin pathway for immune system protection. Ficolin-2 and 3 have been identified in patients with interstitial lung diseases (ILD) and their function in these diseases is currently being explored. In contrast, the functional role of ficolin-1 in pulmonary fibrosis is still elusive and remains to be elucidated. The expression of ficolin-1 in the plasma of idiopathic pulmonary fibrosis (IPF) and connective tissue disease (CTD)-ILD patients was first determined. As the orthologue of human ficolin-1, ficolin-B knockout and ficolin-B overexpression were used to establish bleomycin (BLM)-induced pulmonary fibrosis mouse model. Co-immunoprecipitation, immunofluorescence and RNA sequencing were utilized to explore and expound on the expression and the functional mechanism of ficolin-1 in pulmonary fibrosis. Compared with healthy controls, plasma ficolin-1 was significantly decreased in patients with IPF and CTD-ILD. In the bleomycin (BLM)-induced mice model, ficolin-B deficiency aggravated lung injury and fibrosis. There was also observed increase in TGF-β1 levels and enhanced downstream signaling. However, the overexpression of ficolin-B showed preventative and therapeutic efficacy against lung fibrosis. Furthermore, coimmunoprecipitation studies revealed the direct interaction between ficolin-1 and TGF-β1 in human plasma, which was further confirmed by the colocalization of ficolin-1 and TGF-β1 in lung tissues. Ficolin-1 inhibits pulmonary fibrosis by directly binding to the key profibrogenic factor TGF-β1, marking it as a potential target for therapy in the treatment of fibrotic lung diseases.


  • Open Access

    Coronary stent implantation links to the occurrence of eosinophilia and interstitial pneumonia: a case report and systematic review

    by Fuyun Zhang, Wei Wang, Yingwei Zhu, Yimin Mao, Tongsheng Wang, Pengfei Gao

    Background: Rapamycin has been extensively utilized for coating coronary artery stents to reduce the occurrence of restenosis, yet there has been limited research on the potential harms of rapamycin-eluting stents. Herein, We report a case of eosinophilia and interstitial pneumonia caused by a cobalt-based alloy stent eluted with rapamycin. Case presentation: The patient was admitted due to fever, cough, and expectoration symptoms. Previously, the patient had undergone a procedure of percutaneous coronary stent implantation in our hospital’s cardiology department, which led to a gradual rise in blood eosinophil count. This time, the eosinophil count was higher than the previous admission. A chest CT scan revealed multiple flocculent density increases in both lungs and bronchiectasis. The rapamycin-eluting stents may have caused eosinophilia and interstitial pneumonia, which improved after administering corticosteroids. A systematic review of relevant literature was conducted to summarize the characteristics of interstitial pneumonia caused by drug-eluting stents. Conclusion: Paclitaxel, everolimus, zotarolimus, and rapamycin are the types of drugs that can lead to drug-eluting stents, and because of the rarity of their onset, clinical doctors must be precise and prompt in diagnosing suspected cases to avoid misdiagnosis and delayed treatment.


  • Open Access

    Diagnostic accuracy of thoracic CT to differentiate transudative from exudative pleural effusion prior to thoracentesis

    by Yan Zhang, Yang Zhang, Wei Wang, Xiaoyu Feng, Jiahuan Guo, Bo Chen, Fuyun Zhang, Huanhuan Wang, Mengnan Fan, Yingwei Zhu, et al.

    Background: Computed tomography (CT) scan is commonly performed for pleural effusion diagnostis in the clinic. However, there are limited data assessing the accuracy of thoracic CT for the separation of transudative from exudative effusions. The study aimed to determine the diagnostic value of thoracic CT in distinguishing transudates from exudates in patients with pleural effusion. Methods: This is a two-center retrospective analysis of patients with pleural effusion, a total of 209 patients were included from The First Affiliated Hospital of Henan University of Science and Technology as the derivation cohort (Luoyang cohort), and 195 patients from the First Affiliated Hospital of Zhengzhou University as the validation cohort (Zhengzhou cohort). Patients who underwent thoracic CT scan followed by diagnostic thoracentesis were enrolled. The optimal cut-points of CT value in pleural fluid (PF) and PF to blood CT value ratio for predicting a transudative vs. exudative pleural effusions were determined in the derivation cohort and further verified in the validation cohort. Results: In the Derivation (Luoyang) cohort, patients with exudates had significantly higher CT value [13.01 (10.01–16.11) vs. 4.89 (2.31–9.83) HU] and PF to blood CT value ratio [0.37 (0.27–0.53) vs. 0.16 (0.07–0.26)] than those with transudates. With a cut-off value of 10.81 HU, the area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of CT value were 0.85, 88.89%, 68.90%, 43.96%, and 95.76%, respectively. The optimum cut-value for PF to blood CT value ratio was 0.27 with AUC of 0.86, yielding a sensitivity of 61.11%, specificity of 86.36%, PPV of 78.57%, and NPV of 73.08%. These were further verified in the Validation (Zhengzhou) cohort. Conclusions: CT value and PF to blood CT value ratio showed good differential abilities in predicting transudates from exudates, which may help to avoid unnecessary thoracentesis.


  • Open Access

    Increased expression of ficolin-1 is associated with airway obstruction in asthma

    by Pengfei Gao, Kun Tang, Yanjiao Lu, Meijia Wang, Wei Wang, Tongsheng Wang, Yuxia Sun, Jianping Zhao, Yimin Mao

    Background: The activated complement cascade is involved in asthmatic airway inflammation. Ficolins are essential for innate immunity and can activate the complement lectin pathway. Despite this, the significance of ficolins in asthma has yet to be determined. This study aimed to explore the presence of ficolins in individuals with asthma and to determine the relationship between ficolins and clinical characteristics. Methods: For the study, 68 asthmatic patients and 30 healthy control subjects were recruited. Enzyme-linked immunosorbent assay was used to determine plasma ficolin-1, ficolin-2, and ficolin-3 concentrations both before and after inhaled corticosteroid (ICS) therapy. Further, the associations of plasma ficolin-1 level with pulmonary function and asthma control questionnaire (ACQ) score were examined in the asthma patients. Results: Patients with asthma exhibited significantly elevated plasma ficolin-1 levels (median, 493.9 ng/mL; IQR, 330.2–717.8 ng/mL) in comparison to healthy controls (median, 330.6 ng/mL; IQR, 233.8–371.1 ng/mL). After ICS treatment, plasma ficolin-1 (median, 518.1 ng/mL; IQR, 330.2–727.0 ng/mL) in asthmatic patients was significantly reduced (median, 374.7 ng/mL; IQR, 254.8–562.5 ng/mL). Additionally, ficolin-1 expressions in plasma were significantly correlated with pulmonary function parameters and ACQ score in asthmatic patients. Asthma patients with higher plasma ficolin-1 levels demonstrated poorer lung function than those with lower plasma ficolin-1 levels. Conclusions: The results revealed that asthmatic patients had higher plasma ficolin-1 concentrations, which decreased after ICS treatment and were linked to their lung function, implying a potential involvement of ficolin-1 in asthma pathogenesis.